Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
2026-05-29 16:11:01 ET
I'm initiating Agios Pharmaceuticals, Inc. ( AGIO ) as a Sell rating. The reason why is because, despite having received regulatory approvals for its first-generation PK activators PYRUKIND [mitapivat] and AQVESME [mitapivat] for the treatment of patients with PK deficiency and thalassemia, respectively, it faces a few problems it has to contend with. It submitted a supplemental New Drug Application [NDA] for mitapivat for the treatment of patients with Sickle Cell Disease [SCD] to the FDA for possible Accelerated Approval. There was agreement that a confirmatory trial would be needed in order to eventually convert such potential Accelerated Approval to a "Full Approval."...
Read the full article on Seeking Alpha
For further details see:
Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class
NASDAQ: AGIO
AGIO Trading
-0.91% G/L:
$28.73 Last:
125,844 Volume:
$28.95 Open:
